Achelios Therapeutics, Inc., based in Chapel Hill, North Carolina, is a privately held specialty bio-pharmaceutical development company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation.
Achelios Therapeutics’ lead reformulation product, TOPOFEN™, pairs its proprietary ACHETOGEL™ delivery technology with the proven NSAID ketoprofen. In pre-clinical and early stage clinical studies, we have shown TOPOFEN™ (ketoprofen) to provide superior tissue penetration compared to other topical formulations currently on the market. Clinical results to date show that our drug formulations offer skin permeation between 4 and 9 times higher than that of leading commercial brands. Furthermore, due to the fact that they bypass the body’s hepatic system, topical products such as TOPOFEN™, are generally regarded as safer alternatives to oral therapies. The lead indication for TOPOFEN ™ is acute migraine, for which the asset recently completed a Phase Ib/IIa clinical trial.
Based on the pre-clinical and clinical data generated for ketoprofen formulations, we believe the TOPOGEL™ technology can be applied to molecules that are similar in structure and mechanism of action. This information supports Achelios Therapeutics’ initiative to pursue development of unique proprietary formulations of other NSAIDs for the indications of migraine prophylaxis, osteoarthritis, sprains and strains, and TMJ disorders. We are also actively pursuing the reformulation of naproxen, diclofenac, and ibuprofen compounds.
The strategy of Achelios Therapeutics is to establish a clinical stage drug development pipeline and to move rapidly to proof-of-concept. Each topically formulated medication developed within our state-of-the-art medication research laboratory in San Diego, California, must impact human therapeutics by decreasing side effects, improving efficacy, and improving time to efficacy. Each new formulation will address a significant unmet medical need.
Achelios Therapeutics is building a strong drug development product portfolio with patent-protected pharmaceutical products, with compositions, and/or method-of-use patents. We pursue a strategy of developing compounds with the intent of out-licensing them to potential partners. Achelios Therapeutics is backed by a management team and board of directors with extensive business experience.